-
Mashup Score: 3Brain Cancer Hope: 19.9 Month Median Survival with New Combo - 3 month(s) ago
Combining olaptesed pegol with bevacizumab and radiotherapy showed a 10-fold improvement in survival rate compared with the standard-of-care among patients with glioblastoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Brain Cancer Hope: 19.9 Month Median Survival with New Combo - 3 month(s) ago
Combining olaptesed pegol with bevacizumab and radiotherapy showed a 10-fold improvement in survival rate compared with the standard-of-care among patients with glioblastoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Olaptesed pegol + bevacizumab and radiotherapy delivered an improved median overall survival of 19.9 months in patients with newly diagnosed glioblastoma, according to the phase 1/2 GLORIA study. #GBM https://t.co/sHAnZkrlYb
-
-
Mashup Score: 9
Purpose Glioblastomas, the most common primary malignant brain tumors in adults, still hold poor prognosis. Corticosteroids, such as dexamethasone, are usually prescribed to reduce peritumoral edema and limit neurological symptoms, although potential detrimental effects of these drugs have been described. The present meta-analysis aimed to explore the association of dexamethasone with overall…
Source: link.springer.comCategories: General Medicine News, Onc News and JournalsTweet-
Arora et al. recently published a meta-analysis in @JNO evaluating dexamethasone and outcomes in #GBM. In 1,257 patients, pre- or perioperative dexamethasone was associated with worse OS/PFS @BWHNeurosurgery @mcphsSOPB @MCPHS @UofSCPharm @RMekary https://t.co/eNs0dsw40p https://t.co/rVWJ3oH5Wm
-
-
Mashup Score: 0Olaptesed Pegol Continues to Improve Survival in Glioblastoma - 4 month(s) ago
The median overall survival at 19 months of patients with glioblastoma continues to benefit from treatment with olaptesed pegol plus radiation and bevacizumab.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Olaptesed pegol + bevacizumab + radiotherapy continues to demonstrate promising survival results in the treatment of patients with glioblastoma, according to 19-month follow-up of the phase 1/2 GLORIA study. #GBM https://t.co/cgTPoxwubr https://t.co/UjiaEOlkAC
-
-
Mashup Score: 0DOC1021 Gains FDA Fast Track Designation in Glioblastoma Multiforme - 6 month(s) ago
A fast track designation has been granted to DOC1021 by the FDA for the treatment of patients with glioblastoma multiforme.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has granted a fast track designation to DOC1021, a dendritic cell vaccine, as a potential treatment option for patients with glioblastoma multiforme. #GBM https://t.co/QIdfmi7Hkm
-
-
Mashup Score: 3Dr. Fahar Merchant Discusses a Treatment to Combat Glioblastoma - 7 month(s) ago
Home > Oncology > Dr. Fahar Merchant Discusses a Treatment to Combat Glioblastoma Medicenna, a clinical-stage immunotherapy company, has made significant progress in the development of MDNA11 and MDNA55, which utilize engineered interleukins, known as Superkines, to modulate the i mmune system and combat challenging diseases like recurrent glioblastoma multiforme—an invariably fatal form of brain cancer—and other end-stage cancers. MDNA55, an empowered Superkine, delivers a potent bacterial toxin directly
Source: www.docwirenews.comCategories: Latest Headlines, Partners & KOLsTweet-
Dr. Fahar Merchant discusses a novel treatment which improves overall survival in glioblastoma. #GBM #glioblastoma #braincancer #neurology https://t.co/PtVTLHko3N https://t.co/NJohiKD1Bx
-
-
Mashup Score: 0Could VAL-083 Address Modest Treatment Efficacy in Glioblastoma? - 8 month(s) ago
Experts believe VAL-083 has the potential to change the way oncologists treat glioblastoma in the future.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Glioblastoma remains a difficult malignancy to treat. However, targeting a novel mechanism of action could be the answer to improving the survival rates for these patients. #bcsm #GBM | @UCSDHealth @DanaFarber https://t.co/sSvKHJplYP
-
-
Mashup Score: 0Combination Treatment May Help Some Patients With Glioblastoma - 8 month(s) ago
Combining immunotherapy with a tumor-targeted virus may help extend survival in some patients with recurrent glioblastoma, according to the results of a trial published in Nature Medicine.
Source: news.feinberg.northwestern.eduCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigators at @LurieCancer @NorthwesternMed found that combining #immunotherapy with a virus engineered to target tumors may help extend survival in patients with #glioblastoma, according to results of a trial in @NatureMedicine: https://t.co/9RNyg2kMQK #BTSM #GBM
-
-
Mashup Score: 0
In an interview with Targeted Oncology, Ahmad Ozair, MBBS, discussed treatments for glioblastoma and a trial evaluating surgically targeted radiation therapy in this patient population.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ahmad Ozair, MBBS, discussed treatments for #glioblastoma and a trial evaluating surgically targeted radiation therapy in this patient population. #GBM | @MiamiCancerInst @BHCancerCare @NeuroAhmad https://t.co/JaDiAHs7H3 https://t.co/LTj1gYDnn6
-
-
Mashup Score: 0Gallium Maltolate Gains FDA ODD for Pediatric GBM - 10 month(s) ago
Gallium maltolate now has been granted an orphan drug designation for adult and pediatric patients with glioblastoma multiforme.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The #FDA has granted an orphan drug designation for gallium maltolate for the treatment of pediatric patients with glioblastoma multiforme. #GBM https://t.co/oa9Jo21ZCB
-
Olaptesed pegol + bevacizumab and radiotherapy delivered an improved median overall survival of 19.9 months in patients with newly diagnosed glioblastoma, according to the phase 1/2 GLORIA study. #GBM https://t.co/sHAnZkrlYb